Israel Expected To OK 5-Year Drug Marketing Exclusivity

Law360, New York (April 21, 2004, 12:00 AM EDT) -- Israel’s cabinet, under pressure from U.S. trade officials, is expected to approve recommendations for drug marketing exclusivity on Sunday, according to a local newspaper report.

The cabinet will hasten approval of the recommendations of an interministerial committee for protecting intellectual property rights for pharmaceuticals, Globes, a business daily, reported on Wednesday.

The interministerial committee recommends setting marketing exclusivity in Israel for international pharmaceutical companies for non-patented ethical drugs, and for drugs whose patents have expired, due to prolonged clinical trials. The five-year exclusivity period will apply...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.